121 related articles for article (PubMed ID: 38864802)
1. A phase I/II study of adoptive SARS-CoV-2-specific T cells in immunocompromised hosts with or at risk of severe COVID-19 infection.
Seng MS; Ng KP; Soh TG; Tan TT; Chan M; Maiwald M; Tan LK; Linn YC; Leung W
Cytotherapy; 2024 May; ():. PubMed ID: 38864802
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
3. Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients.
Papayanni PG; Chasiotis D; Koukoulias K; Georgakopoulou A; Iatrou A; Gavriilaki E; Giannaki C; Bitzani M; Geka E; Tasioudis P; Chloros D; Fylaktou A; Kioumis I; Triantafyllidou M; Dimou-Besikli S; Karavalakis G; Boutou AK; Siotou E; Anagnostopoulos A; Papadopoulou A; Yannaki E
Clin Infect Dis; 2021 Dec; 73(11):2073-2082. PubMed ID: 33905481
[TBL] [Abstract][Full Text] [Related]
4. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
La Rosa C; Chiuppesi F; Park Y; Zhou Q; Yang D; Gendzekhadze K; Ly M; Li J; Kaltcheva T; Ortega Francisco S; Gutierrez MA; Ali H; Otoukesh S; Amanam I; Salhotra A; Pullarkat VA; Aldoss I; Rosenzweig M; Aribi AM; Stein AS; Marcucci G; Dadwal SS; Nakamura R; Forman SJ; Al Malki MM; Diamond DJ
Front Immunol; 2023; 14():1114131. PubMed ID: 36936918
[TBL] [Abstract][Full Text] [Related]
5. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
6. Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.
Gopcsa L; Réti M; Andrikovics H; Bobek I; Bekő G; Bogyó J; Ceglédi A; Dobos K; Giba-Kiss L; Jankovics I; Kis O; Lakatos B; Mathiász D; Meggyesi N; Miskolczi G; Németh N; Paksi M; Riczu A; Sinkó J; Szabó B; Szilvási A; Szlávik J; Tasnády S; Reményi P; Vályi-Nagy I
Geroscience; 2024 Feb; 46(1):1083-1106. PubMed ID: 37414968
[TBL] [Abstract][Full Text] [Related]
7. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
[TBL] [Abstract][Full Text] [Related]
8. Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19.
García-Ríos E; Leivas A; Mancebo FJ; Sánchez-Vega L; Lanzarot D; Aguado JM; Martínez-López J; Paciello ML; Pérez-Romero P
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327433
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
[TBL] [Abstract][Full Text] [Related]
10. Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.
Bonifacius A; Tischer-Zimmermann S; Santamorena MM; Mausberg P; Schenk J; Koch S; Barnstorf-Brandes J; Gödecke N; Martens J; Goudeva L; Verboom M; Wittig J; Maecker-Kolhoff B; Baurmann H; Clark C; Brauns O; Simon M; Lang P; Cornely OA; Hallek M; Blasczyk R; Seiferling D; Köhler P; Eiz-Vesper B
Front Bioeng Biotechnol; 2022; 10():867042. PubMed ID: 35480981
[No Abstract] [Full Text] [Related]
11. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
[TBL] [Abstract][Full Text] [Related]
12. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
13. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
15. Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination.
Fernández-González M; Agulló V; Padilla S; García JA; García-Abellán J; Botella Á; Mascarell P; Ruiz-García M; Masiá M; Gutiérrez F
Clin Infect Dis; 2022 Aug; 75(1):e338-e346. PubMed ID: 34893816
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; Aguilar-Gallardo C; Montoro J; Francés-Gómez C; Latorre V; Luna I; Planelles D; Carrasco MP; Gómez MD; González-Barberá EM; Aguado C; Sempere A; Solves P; Gómez-Seguí I; Balaguer-Rosello A; Louro A; Perla A; Larrea L; Sanz J; Arbona C; de la Rubia J; Geller R; Sanz MÁ; Sanz G; Luis Piñana J
Transpl Infect Dis; 2021 Aug; 23(4):e13602. PubMed ID: 33728702
[TBL] [Abstract][Full Text] [Related]
17. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.
Kim N; Lee JM; Oh EJ; Jekarl DW; Lee DG; Im KI; Cho SG
Front Immunol; 2021; 12():751869. PubMed ID: 35003063
[TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.
Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS
Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557
[TBL] [Abstract][Full Text] [Related]
19. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
